Literature DB >> 2503527

Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion.

J F Cajot1, W D Schleuning, R L Medcalf, J Bamat, J Testuz, L Liebermann, B Sordat.   

Abstract

A cosmid (cos pUK0322) harboring the complete human urokinase-type plasminogen activator (u-PA) gene and Geneticin resistance as a selectable marker was isolated from a human genomic library and characterized. After transfection of cos pUK0322 into mouse L cells and selection, several plasminogen activator (PA)-expressing clones were obtained and one (LuPA) was chosen for additional study. The PA expressed was identical to human pro-u-PA in enzymatic, electrophoretic, and antigenic properties. The expression of PA was stable over 50 population doublings. The regulation of the transfected gene was studied by treatment of the cells with various hormones and other effectors. Expression of PA activity was inhibited fivefold by dexamethasone and stimulated two- to threefold by agonists of the adenylate cyclase dependent pathway of signal transduction, such as dibutyryl cyclic AMP and cholera and pertussis toxins. The modulation of PA activity was associated with corresponding changes in mRNA steady-state levels. The phenotypic changes associated with pro-u-PA expression were analyzed in vitro by degradation of 3H-labeled extracellular matrix (ECM), invasion of a matrigel basement membrane analogue, and by light and electron microscopy. LuPA cells and reference HT-1080 fibrosarcoma cells, in contrast to control Lneo cells transfected with the neomycin resistance gene, degraded the ECM and invaded the matrigel basement membrane. Matrix degradation correlated with the modulation of pro-u-PA gene expression as it was inhibited by dexamethasone and promoted by dibutyryl cyclic AMP. Inhibition of PA or plasmin using anti-u-PA IgG or aprotinin prevented ECM degradation and invasion. These results demonstrate that u-PA expression alone is sufficient to confer to a cell an experimental invasive phenotype.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2503527      PMCID: PMC2115719          DOI: 10.1083/jcb.109.2.915

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  52 in total

1.  Human primary colon carcinomas xenografted into nude mice. I. Characterization of plasminogen activators expressed by primary tumors and their xenografts.

Authors:  J F Cajot; B Sordat; E K Kruithof; F Bachmann
Journal:  J Natl Cancer Inst       Date:  1986-09       Impact factor: 13.506

2.  Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.

Authors:  P A Andreasen; L S Nielsen; P Kristensen; J Grøndahl-Hansen; L Skriver; K Danø
Journal:  J Biol Chem       Date:  1986-06-15       Impact factor: 5.157

3.  A rapid method for the preparation of multiple samples of eucaryotic DNA.

Authors:  C D Reymond
Journal:  Nucleic Acids Res       Date:  1987-10-12       Impact factor: 16.971

4.  Electrophoretic separations of large DNA molecules by periodic inversion of the electric field.

Authors:  G F Carle; M Frank; M V Olson
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

5.  DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells.

Authors:  M Wigler; A Pellicer; S Silverstein; R Axel; G Urlaub; L Chasin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

6.  Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex.

Authors:  M Philips; A G Juul; S Thorsen
Journal:  Biochim Biophys Acta       Date:  1984-11-06

7.  Antibodies to plasminogen activator inhibit human tumor metastasis.

Authors:  L Ossowski; E Reich
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

8.  Plasminogen activator and mouse spermatozoa: urokinase synthesis in the male genital tract and binding of the enzyme to the sperm cell surface.

Authors:  J Huarte; D Belin; D Bosco; A P Sappino; J D Vassalli
Journal:  J Cell Biol       Date:  1987-05       Impact factor: 10.539

9.  Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family.

Authors:  H Pannekoek; H Veerman; H Lambers; P Diergaarde; C L Verweij; A J van Zonneveld; J A van Mourik
Journal:  EMBO J       Date:  1986-10       Impact factor: 11.598

10.  Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.

Authors:  J Pöllänen; K Hedman; L S Nielsen; K Danø; A Vaheri
Journal:  J Cell Biol       Date:  1988-01       Impact factor: 10.539

View more
  28 in total

1.  Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.

Authors:  R W Stephens; H Tapiovaara; T Reisberg; J Bizik; A Vaheri
Journal:  Cell Regul       Date:  1991-12

2.  Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.

Authors:  R Mazzieri; L Masiero; L Zanetta; S Monea; M Onisto; S Garbisa; P Mignatti
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

3.  Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.

Authors:  P H Quax; N Pedersen; M T Masucci; E J Weening-Verhoeff; K Danø; J H Verheijen; F Blasi
Journal:  Cell Regul       Date:  1991-10

Review 4.  The role of proteolytic enzymes in cancer invasion and metastasis.

Authors:  M J Duffy
Journal:  Clin Exp Metastasis       Date:  1992-05       Impact factor: 5.150

Review 5.  Tumoral invasion in the central nervous system.

Authors:  Y A De Clerck; H Shimada; I Gonzalez-Gomez; C Raffel
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.

Authors:  C Kunz; S Pebler; J Otte; D von der Ahe
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

7.  Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion.

Authors:  H Kobayashi; H Shinohara; H Ohi; M Sugimura; T Terao; M Fujie
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

Review 8.  Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis.

Authors:  R S Kerbel; I Cornil; D Theodorescu
Journal:  Cancer Metastasis Rev       Date:  1991-10       Impact factor: 9.264

9.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  Autocrine angiotensin system regulation of bovine aortic endothelial cell migration and plasminogen activator involves modulation of proto-oncogene pp60c-src expression.

Authors:  L Bell; D J Luthringer; J A Madri; S L Warren
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.